Exelixis
Exelixis is a Bay Area oncology biotechnology company developing small molecule and biotherapeutic cancer treatments, including flagship product CABOMETYX (cabozantinib).
Exelixis is an oncology-focused biotechnology company founded in 1994 and headquartered in the Bay Area, where it operates a state-of-the-art campus. The firm develops cancer treatments spanning small molecule therapeutics and biotherapeutics, drawing on expertise in chemistry, biology, genomics and data-driven drug discovery. It employs more than 1,000 people and maintains collaborations with clinicians worldwide.
The company's flagship commercial product is CABOMETYX (cabozantinib), a small molecule therapeutic used both as a standalone treatment and in combination with immune checkpoint inhibitors across multiple cancer types. Beyond this, Exelixis pursues a diversified portfolio of therapies with multiple mechanisms of action, supported by decades of investment in research and development.
Exelixis works across the drug development chain, from discovery through commercialisation, and places weight on strategic partnerships in discovery, development and commercialisation. Its stated mission is to develop life-enhancing cancer treatments and to establish new standards of care with clinicians around the world.